Britain and America have announced a significant bilateral deal that will keep no levies on UK pharmaceutical shipments going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the public health system. This move secures that duties on these vital exports will remain at zero for a timeframe of 36 months.
This development follows earlier threats to dramatically increase import taxes on patented drug imports, with increases floated as high as one hundred percent.
"This deal between the Britain bolsters the global environment for cutting-edge drugs and introduces much-needed equity to American-British medicine commerce," an announcement said.
Commercial Importance
Medicines constitute one of the the United Kingdom's biggest goods shipped to the United States, which is clearly the largest destination for large British pharmaceutical firms.
Export figures show that in the year leading up to September, the UK shipped drugs worth £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This guarantee protects work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a minister stated.
Specific British Pledges
The deal entails several notable changes from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. Previously, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a ongoing dispute between the drug companies and the ministers over drug pricing and approval rates.
These tensions were exacerbated by claims that US consumers were charged significantly more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
